DFTX (Definium Therapeutics) EBIT: $-231.42 Mil (TTM As of Mar. 2026)

What is Definium Therapeutics EBIT?

Definium Therapeutics DFTX +1.07% 32 EBIT is $-231.42 Mil as of Mar. 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Definium Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-75.85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-231.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Definium Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -318.46%. Definium Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Definium Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3.91%.

Definium Therapeutics (NAS:DFTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Definium Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-236.88 * ( 1 - 0% )	/	( (71.152	+	77.614)	/ 2 )
=	-236.88	/	74.383
=	-318.46 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	440.1	-	16.326	-	( 411.593	-	max(0, 66.698	-	419.32	+	411.593	))
=	71.152

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	401.293	-	24.228	-	( 373.422	-	max(0, 81.112	-	380.563	+	373.422	))
=	77.614

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Definium Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-303.412	/	( ( (0 + max(-58.971, 0))	+	(0 + max(-73.971, 0)) )	/	2 )
=	-303.412	/	( ( 0	+	0 )	/	2 )
=	-303.412	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	7.727)	-	(16.326	+	0	+	50.372)
=	-58.971

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	7.141)	-	(24.228	+	0	+	56.884)
=	-73.971

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Definium Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-231.418	/	5911.595
	=	-3.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Definium Therapeutics EBIT Related Terms

Definium Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Definium Therapeutics's EBIT can be seen below:

Definium Therapeutics EBIT Chart

Definium Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-93.85

-66.33

-94.81

-106.40

-178.31

Definium Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-22.75	-40.41	-65.99	-49.17	-75.85

DFTX vs LGND, XENE, CGON: EBIT Comparison

For the Biotechnology subindustry, Definium Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Definium Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Definium Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Definium Therapeutics's EV-to-EBIT falls into.

Save Embed

32GF Score

Definium Therapeutics Inc DFTX

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Definium Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-231.42 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-231.42 Mil mean?

Definium Therapeutics (DFTX) has a EBIT of $-231.42 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Definium Therapeutics.

Is Definium Therapeutics' EBIT too high?

Definium Therapeutics' current EBIT is $-231.42 Mil. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Definium Therapeutics' EBIT compare to LGND and XENE?

Definium Therapeutics' EBIT of $-231.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Definium Therapeutics. Definium Therapeutics's current EBIT is $-231.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Definium Therapeutics stock overvalued right now?

Definium Therapeutics (DFTX) has a current EBIT of $-231.42 Mil. The current EBIT is $-231.42 Mil. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current EBIT is $-231.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies LGND XENE CGON LEGN TVTX ORKA COGT CRSP SRRK MANE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges MMQ0:Germany

Address One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website https://www.definiumtx.com

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

32GF Score

Get the complete analysis for DFTX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.04

Price

View DFTX Analysis

See EBIT data for all stocks →